Femur fractures:References

Abrahamsen B. Subtrochanteric And Diaphyseal Femur Fractures in Patients Treated with Alendronate: A Register-Based National Cohort Study. J Bone Miner Res 2008.

Abrahamsen B. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010;95(12):5258-65.

Agarwal S. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature. Acta Orthop Belg 2010;76(5):567-71.

Ali T. Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing 2009;38(5):625-6.

Armamento-Villareal R. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009;85(1):37-44.

Armamento-Villareal R. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006;355(19):2048-50.

Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop 2008;79(4):459-60.

Aspenberg P. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack. Acta Orthop 2010;81(4):460-2.

Atik OS. Insufficiency femoral fractures in patients undergoing prolonged alendronate therapy. Eklem Hastalik Cerrahisi 2010;21(1):56-9.

Banffy MB. Nonoperative versus Prophylactic Treatment of Bisphosphonate-associated Femoral Stress Fractures. Clin Orthop Relat Res 2011.

Bauer DC. Bisphosphonate use and atypical femoral fractures: getting down to brass tacks. J Clin Endocrinol Metab 2010;95(12):5207-9.

Bunning RD. Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM R 2010;2(1):76-80.

Burr DB. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res 2009;27(10):1288-92.

. Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastases. . Radiology Case Reports [online] 3:232 2008.

Capeci CM. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009;91(11):2556-61.

Cermak K. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 2010;468(7):1991-6.

Chan SS. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol 2010;194(6):1581-6.

Cheung RK. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007;13(6):485-9.

Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 2010;92(5):679-86.

Demiralp B. Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007;127(7):597-601.

Edwards MH. Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 2010;21(4):701-3.

Falkenberg MP. Atypical femoral fractures: a complication of prolonged bisphosphonate therapy? Med J Aust 2011;194(2):102-3; author reply 3.

Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009;7(1):12-7.

Girgis CM. Atypical femur fractures: a complication of prolonged bisphosphonate therapy? Med J Aust 2010;193(4):196-8.

Giusti A. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2010.

Giusti A. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010;47(2):169-80.

Goddard MS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009;32(8).

Goh SK. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89(3):349-53.

Gomberg SJ. Teriparatide, Vitamin D, and Calcium Healed Bilateral Subtrochanteric Stress Fractures in a Postmenopausal Woman with a 13-Year History of Continuous Alendronate Therapy. J Clin Endocrinol Metab 2011.

Grasko JM. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. J Oral Maxillofac Surg 2009;67(3):645-9.

Ha YC. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 2010;468(12):3393-8.

Horning JA. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis. Orthopedics 2010;33(12):902-5.

Imai K. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007;25(5):333-6.

Ing-Lorenzini K. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009;32(9):775-85.

Isaacs JD. Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy. Clin Orthop Relat Res 2010.

Jobke B. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res 2009;50(1):46-54.

Kim SY. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2010.

Koh JS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 2010;24(2):75-81.

Kwek EB. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39(2):224-31.

Kwek EB. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008;359(3):316-7; author reply 7-8.

Lee P. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008;359(3):317; author reply -8.

Lee P. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007;30(7):590-7.

Lenart BA. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358(12):1304-6.

Lenart BA. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2008;20:1457-8.

. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Reports 2009.

Meijer WM. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 2008.

Napoli N. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int 2009.

Neviaser AS. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22(5):346-50.

Ng YH. Femoral shaft fractures in the elderly - Role of prior bisphosphonate therapy. Injury 2011.

Nieves JW. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010;8(1):34-9.

Odvina CV. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009.

Odvina CV. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294-301.

Osugi K. Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases. Acta Orthop 2011;82(1):112-3.

Ott SM. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2010;33(7):468.

Park-Wyllie LY. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Jama 2011;305(8):783-9.

Patel VC. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use. Orthopedics 2010;33(10):775.

Rizzoli R. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22(2):373-90.

Rogers LF. FDA statement on relationship between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures: a considered opinion. AJR Am J Roentgenol 2010;195(3):563-6.

Rozental TD. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 2009;34(4):595-602.

Sayed-Noor AS. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report. Acta Orthop 2008;79(4):565-7.

Sayed-Noor AS. Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy. Clin Orthop Relat Res 2009.

Schilcher J. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009:1-3.

Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006;61(1):31-3.

Schneider JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009;64(1):18-23.

Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010;304(13):1480-4.

Shane E. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25(11):2267-94.

Silverman SL. Bisphosphonates and atypical femoral fractures. N Engl J Med 2010;363(11):1083; author reply 4-5.

Solomon DH. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 2009;20(6):895-901.

Solomon DH. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009;21(4):363-8.

Somford MP. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009;24(10):1736-40.

Spangler L. Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures. Osteoporos Int 2010.

Vasikaran SD. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study. Osteoporos Int 2009;20(8):1457-8.

Venkatanarasimha N. Subtrochanteric femoral insufficiency fractures related to the use of long-term bisphosphonates: a pictorial review. Emerg Radiol 2010.

Vestergaard P. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011;22(3):993-1001.

Visekruna M. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948-52.

Wernecke G. Case Report of Spontaneous, Nonspinal Fractures in a Multiple Myeloma Patient on Long-term Pamidronate and Zoledronic Acid. HSS J 2008;4(2):123-7.

Wright RC. Bilateral femoral neck stress fractures in a fire academy student. Orthopedics 2010;33(10):767.

Updated 3/31/11